Novo Nordisk, the Danish drug maker of the wildly successful obesity drugs, Wegovy and Ozempic, said it plans to invest $4.1 billion for a new plant in the United States to increase the manufacturing capacity of its high demand drugs. The new plant will be in Clayton, North Carolina, where the company plans to produce current and future injectable treatments for people with obesity and other serious chronic diseases. These mainly include weight loss drug Wegovy and diabetes treatment Ozempic, among others. As per reports, demand for Wegovy and Ozempic have grown significantly over supply in th…